Surufatinib is a novel oral angio-immuno tyrosine kinase inhibitor (TKI) with multiple targets including vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, fibroblast growth factor receptor type 1 (FGFR1) and colony-stimulating factor-1 receptor (CSF-1R).19 It is the first targetable therapeutic drug approved globally to treat NET from all sources of organs, including lung.19 There is evidence that VEGFR, FGFR, and CSF-1R play important roles in the regulations of tumor immunity. Here, CSF1R is linked to neoplasm.